BACKGROUND: Due to restricted expression in normal tissues cancer/testis (C/T) antigens represent candidate molecules for immunotherapy of cancer. NY-ESO-1 is a well-studied C/T antigen with unknown expression and immunogenicity in prostate cancer (PC) patients. METHODS: NY-ESO-1 expression was determined by immunohistochemistry and humoral immune responses against NY-ESO-1 assessed by enzyme-linked immuno-sorbent assay (ELISA) and Western blotting. Protein expression and serological responses were correlated with clinical findings and survival. RESULTS: NY-ESO-1 expression was found in biopsies from 2 of 66 localized PC and 7/48 hormone refractory prostate cancer (HRPC) patients, respectively. Anti-NY-ESO-1 antibodies were detected in sera from 1 of 112 localized PC and 18 of 95 HRPC patients. Two of four HRPC patients with NY-ESO-1 positive biopsies had mounted a serological response. Positive anti-NY-ESO-1 titers were correlated with poor survival in HRPC patients. CONCLUSIONS: NY-ESO-1 is expressed in a subset of HRPC patients and, together with other C/T antigens, may serve as a target antigen for development of immunotherapy of PC. Spontaneous serological responses against NY-ESO-1 may be associated with poor survival. Copyright 2004 Wiley-Liss, Inc.
BACKGROUND: Due to restricted expression in normal tissues cancer/testis (C/T) antigens represent candidate molecules for immunotherapy of cancer. NY-ESO-1 is a well-studied C/T antigen with unknown expression and immunogenicity in prostate cancer (PC) patients. METHODS:NY-ESO-1 expression was determined by immunohistochemistry and humoral immune responses against NY-ESO-1 assessed by enzyme-linked immuno-sorbent assay (ELISA) and Western blotting. Protein expression and serological responses were correlated with clinical findings and survival. RESULTS:NY-ESO-1 expression was found in biopsies from 2 of 66 localized PC and 7/48 hormone refractory prostate cancer (HRPC) patients, respectively. Anti-NY-ESO-1 antibodies were detected in sera from 1 of 112 localized PC and 18 of 95 HRPC patients. Two of four HRPC patients with NY-ESO-1 positive biopsies had mounted a serological response. Positive anti-NY-ESO-1 titers were correlated with poor survival in HRPC patients. CONCLUSIONS:NY-ESO-1 is expressed in a subset of HRPC patients and, together with other C/T antigens, may serve as a target antigen for development of immunotherapy of PC. Spontaneous serological responses against NY-ESO-1 may be associated with poor survival. Copyright 2004 Wiley-Liss, Inc.
Authors: Prakash Kulkarni; Takumi Shiraishi; Krithika Rajagopalan; Robert Kim; Steven M Mooney; Robert H Getzenberg Journal: Nat Rev Urol Date: 2012-06-19 Impact factor: 14.432
Authors: Guru Sonpavde; Mingjun Wang; Leif E Peterson; Helen Y Wang; Teresa Joe; Martha P Mims; Dov Kadmon; Michael M Ittmann; Thomas M Wheeler; Adrian P Gee; Rong-Fu Wang; Teresa G Hayes Journal: Invest New Drugs Date: 2013-04-23 Impact factor: 3.850
Authors: Sid P Kerkar; Zeng-Feng Wang; Jerzy Lasota; Tristen Park; Krishna Patel; Eric Groh; Steven A Rosenberg; Markku M Miettinen Journal: J Immunother Date: 2016-05 Impact factor: 4.456
Authors: William S Chen; Winston A Haynes; Rebecca Waitz; David Y Oh; John C Shon; Felix Y Feng; Kathy Kamath; Agustin Vega-Crespo; Raunak Shrestha; Minlu Zhang; Adam Foye; Ignacio Baselga Carretero; Ivan Perez Garcilazo; Meng Zhang; Shuang G Zhao; Martin Sjöström; David A Quigley; Jonathan Chou; Tomasz M Beer; Matthew Rettig; Martin Gleave; Christopher P Evans; Primo Lara; Kim N Chi; Robert E Reiter; Joshi J Alumkal; Alan Ashworth; Rahul Aggarwal; Eric J Small; Patrick S Daugherty; Antoni Ribas Journal: Clin Cancer Res Date: 2020-09-23 Impact factor: 12.531